Profound Medical is trying to turn TULSA from a lumpy capital-placement story into a reimbursed, high-throughput prostate-ablation franchise. The second-quarter print did not settle that debate. Record purchase orders exceeded $7 million. A late-June logistics bottleneck then pushed a large block of TULSA shipments into July, so reported revenue barely grew. Investors are being asked to trust the order book and a reiterated full-year bar rather than the income statement that just printed.
Same-store utilization is the more honest test. The TULSA INDEX20 cohort slipped sequentially even as first-half procedure volume still grew versus the year-ago stretch. Recurring disposable and warranty revenue was $1.6 million. That is not the signature of a platform already running full treatment days. Gross margin reached 78%. Mix favored converting leased systems into capital sales rather than a sudden jump in procedure density.
Cash still funds the ramp, but first-half operating burn consumed a large slice of the December raise. Management kept the full-year revenue bar at $25 million. That guide implies a steep second-half conversion of the order book and a qualified pipeline measured at $70 million. The question the next two prints have to answer is whether TULSA utilization and private-payer coverage can turn that pipeline into cash before the bank liquidity floor becomes the binding constraint.